Other compounds and targets in non-small cell lung cancer

Victoria Villaflor*, Philip Bonomi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


It has become increasingly apparent in recent years that a therapeutic plateau has been reached for patients with advanced stage non-small cell lung cancer (NSCLC) treated with conventional cytotoxic agents. As a result, investigators have directed their efforts toward the development of treatments encompassing novel targeted agents. Apoptosis is one of many cellular pathways currently under investigation as a therapeutic target for the treatment of NSCLC. Anti-inflammatory agents, including cyclooxygenase inhibitors, have been shown to inhibit apoptosis and appear promising based on preclinical studies. However, several phase II studies indicate that this therapeutic strategy is unlikely to be successful. In contrast, the proteosome inhibitor bortezomib has shown promise in preliminary studies, and further efforts to elucidate the role this agent may play in the treatment of NSCLC are ongoing. Agonists of the tumor necrosis factor-related, apoptosis-inducing ligand have also entered into early clinical studies in patients with NSCLC. Further studies will be needed to fully clarify how agents targeting the apoptotic pathway can be used in the treatment of NSCLC, but the results of current clinical trials suggest that certain agents may be active.

Original languageEnglish (US)
Pages (from-to)30-36
Number of pages7
JournalSeminars in Oncology
Issue numberSUPPL. 10
StatePublished - Dec 2005

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Other compounds and targets in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this